The market for intestinal lysis surges, consistency evaluation needs to be improved

Introduction: Intestinal dissolved preparations market analysis
the development of consistency evaluation, opened a new model of domestic generic drugs, and then the comprehensive development of the collection policy, China's generic drug market officially entered the era of low profitsThe publication of the national version of the supplementary drug catalog, THE DRGS payment model gradually launched, to promote hospitals to improve efficiency, save costs, to provide patients with reasonable medical servicesIn the face of structural changes in the pharmaceutical industry, the development of differentiated products, there is a way to break the groundat home and abroad, the drug research and development boom is developing from meeting the basic needs of clinical practice to improving the patient's drug experience and improving the quality of life of patients, with high efficiency, long-term, low dose, low toxicity, targeting, convenience and other new drug preparations have become the focus of enterpriseconcernHigh-end preparations such as oral slow-controlled release agents, liposomes/microspheres, such as long-acting injections, transdermal and mucous membrane administration systems, inhalation preparations, etchave been widely used in various clinical fieldsthe characteristics of intestinal solubosis
enterosolutis, intestinal-soluble capsules, slow release tablets and slow release capsules and other high-end preparations with its better compliance, tolerance, ease of use and other advantages have gradually developed into the main products in the field of treatment, the domestic and foreign markets as a whole showed a good growth trendHigh-end preparations due to the existence of technical barriers, the domestic market is mainly occupied by the original research manufacturers, the current domestic development of generic drugs is relatively slow, the overall competitive pressure is smallFor generic selling enterprises, the development of high-end preparations with high technical barriers is expected to help enterprises optimize the resource structure, based on the advantages of products, avoid the ordinary preparation of crowded circuit, in the future market has a higher competitiveness and profit margins, the development opportunities are greaterdomestic and foreign market profile
International market (Newport Statistics) in 2019 and 2018, sales of major intestinal solute preparations were 18 billion u.Sdollars and 19 billion U.Sdollars, the overall performance of the international market was stableThe main contributions come from the following areas: proton pump inhibitors, anti-inflammatory drugs, cardiovascular disease, depression drugs, anti-infective drugs and immunosuppressantsdomestic market (minnet): China's urban public hospital statistics, 2016-2018, the domestic intestinal solute preparations market increased year by year, in 2016 public urban hospital sales have exceeded the 10 billion yuan mark, in 2016 the domestic clinical main intestinal solute preparation scant city public hospital market capacity of 10,097 million yuan, to expand to 12.365 billion yuan in 2018, the rapid growth rate of domestic clinical demand The main market contribution drug treatment field to match the international market demand 's main product introduction the market for nearly $20 billion in intestinal dissolved preparations is mainly contributed by the following 18 active ingredients, its products are mainly concentrated in the proton pump inhibitor class (about 30% of the total product), such as omeprazole, lansolaazole, rebellaazole, Aiomeprazole, etc.; Proton Pump Inhibitors (PPIs) since the first PPI omeprazole was introduced in 1980s, PPIs have been in clinical use for more than 30 years and have gradually replaced histamine H2 receptor antagonists, which currently account for up to 90% of the market Domestic listing of the six PPIs market size of more than 1 billion yuan, the overall competitive landscape is stable, product replacement is slow, in the future for a long time still dominate, and most ppIs are national health insurance products, to ensure the reasonableness and accessibility of clinical drugs for patients, reduce the economic burden at present, the domestic listed proton pump inhibitor products only omeprazole intestinal capsules 1 variety through consistency evaluation, other rapid lyse products for Theomeraazole magnesium intestinal tablets (2 according to the new 4 categories declared), Aiomeprazole magnesium intestinal capsules (3 by the new Class 3 declaration), right Lansola intestinal soluble capsules (2 reported by the new 3), omeprazole intestinal tablets and sodium poise intestinal tablets (respectively, enterprises submitted a consistency assessment price supplement application), Rebellasssodium intestinal tablets (Haassen filed for BE filing) in addition, more suitable for infants and low-age children and patients with swallowing difficulties to take omeprazole intestinal dried suspension, protoazole intestinal dried suspension agent and Aiomeprazole intestinal dried suspension has not yet achieved domestic and import, domestic no public research and development dynamics, competitive pressure, can be accompanied by other intestinal tablets, capsule synchronous development, improve the product of the clinical needs of pediatric patients to improve competitiveness other therapeutic areas represent drugs